12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
This is a 12-month, single-arm, real-world study designed to evaluate the efficacy and safety of lecanemab (10 mg/kg administered every two weeks) in patients with early Alzheimer's disease, including mild cognitive impairment (MCI) due to AD or mild AD dementia, confirmed by amyloid-positive A-PET scans. The study will enroll 80 participants, with both retrospective and prospective data collection.